196 related articles for article (PubMed ID: 17023585)
1. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.
Atanackovic D; Arfsten J; Cao Y; Gnjatic S; Schnieders F; Bartels K; Schilling G; Faltz C; Wolschke C; Dierlamm J; Ritter G; Eiermann T; Hossfeld DK; Zander AR; Jungbluth AA; Old LJ; Bokemeyer C; Kröger N
Blood; 2007 Feb; 109(3):1103-12. PubMed ID: 17023585
[TBL] [Abstract][Full Text] [Related]
2. Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation.
Luetkens T; Kobold S; Cao Y; Ristic M; Schilling G; Tams S; Bartels BM; Templin J; Bartels K; Hildebrandt Y; Yousef S; Marx A; Haag F; Bokemeyer C; Kröger N; Atanackovic D
Cancer Immunol Immunother; 2014 Nov; 63(11):1151-62. PubMed ID: 25078248
[TBL] [Abstract][Full Text] [Related]
3. Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma.
Atanackovic D; Blum I; Cao Y; Wenzel S; Bartels K; Faltz C; Hossfeld DK; Hegewisch-Becker S; Bokemeyer C; Leuwer R
Cancer Biol Ther; 2006 Sep; 5(9):1218-25. PubMed ID: 16929165
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy.
de Carvalho F; Vettore AL; Inaoka RJ; Karia B; Andrade VC; Gnjatic S; Jungbluth AA; Colleoni GW
Cancer Immun; 2011 Jan; 11():1. PubMed ID: 21247062
[TBL] [Abstract][Full Text] [Related]
5. SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs.
Taylor BJ; Reiman T; Pittman JA; Keats JJ; de Bruijn DR; Mant MJ; Belch AR; Pilarski LM
J Immunother; 2005; 28(6):564-75. PubMed ID: 16224274
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.
Stadtmauer EA; Faitg TH; Lowther DE; Badros AZ; Chagin K; Dengel K; Iyengar M; Melchiori L; Navenot JM; Norry E; Trivedi T; Wang R; Binder GK; Amado R; Rapoport AP
Blood Adv; 2019 Jul; 3(13):2022-2034. PubMed ID: 31289029
[TBL] [Abstract][Full Text] [Related]
7. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events.
Jäger E; Stockert E; Zidianakis Z; Chen YT; Karbach J; Jäger D; Arand M; Ritter G; Old LJ; Knuth A
Int J Cancer; 1999 Oct; 84(5):506-10. PubMed ID: 10502728
[TBL] [Abstract][Full Text] [Related]
8. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1.
Maio M; Coral S; Sigalotti L; Elisei R; Romei C; Rossi G; Cortini E; Colizzi F; Fenzi G; Altomonte M; Pinchera A; Vitale M
J Clin Endocrinol Metab; 2003 Feb; 88(2):748-54. PubMed ID: 12574209
[TBL] [Abstract][Full Text] [Related]
9. NY-ESO-1 expression in meningioma suggests a rationale for new immunotherapeutic approaches.
Baia GS; Caballero OL; Ho JS; Zhao Q; Cohen T; Binder ZA; Salmasi V; Gallia GL; Quinones-Hinojosa A; Olivi A; Brem H; Burger P; Strausberg RL; Simpson AJ; Eberhart CG; Riggins GJ
Cancer Immunol Res; 2013 Nov; 1(5):296-302. PubMed ID: 24777967
[TBL] [Abstract][Full Text] [Related]
10. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
11. NY-ESO-1 immunotherapy for multiple myeloma.
Szmania S; Tricot G; van Rhee F
Leuk Lymphoma; 2006 Oct; 47(10):2037-48. PubMed ID: 17071474
[TBL] [Abstract][Full Text] [Related]
12. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
Rodolfo M; Luksch R; Stockert E; Chen YT; Collini P; Ranzani T; Lombardo C; Dalerba P; Rivoltini L; Arienti F; Fossati-Bellani F; Old LJ; Parmiani G; Castelli C
Cancer Res; 2003 Oct; 63(20):6948-55. PubMed ID: 14583496
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
Jäger E; Chen YT; Drijfhout JW; Karbach J; Ringhoffer M; Jäger D; Arand M; Wada H; Noguchi Y; Stockert E; Old LJ; Knuth A
J Exp Med; 1998 Jan; 187(2):265-70. PubMed ID: 9432985
[TBL] [Abstract][Full Text] [Related]
14. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ
Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938
[TBL] [Abstract][Full Text] [Related]
15. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue.
Li M; Yuan YH; Han Y; Liu YX; Yan L; Wang Y; Gu J
Clin Cancer Res; 2005 Mar; 11(5):1809-14. PubMed ID: 15756003
[TBL] [Abstract][Full Text] [Related]
16. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.
Kawada J; Wada H; Isobe M; Gnjatic S; Nishikawa H; Jungbluth AA; Okazaki N; Uenaka A; Nakamura Y; Fujiwara S; Mizuno N; Saika T; Ritter E; Yamasaki M; Miyata H; Ritter G; Murphy R; Venhaus R; Pan L; Old LJ; Doki Y; Nakayama E
Int J Cancer; 2012 Feb; 130(3):584-92. PubMed ID: 21413013
[TBL] [Abstract][Full Text] [Related]
17. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
Sharma P; Gnjatic S; Jungbluth AA; Williamson B; Herr H; Stockert E; Dalbagni G; Donat SM; Reuter VE; Santiago D; Chen YT; Bajorin DF; Old LJ
Cancer Immun; 2003 Dec; 3():19. PubMed ID: 14680360
[TBL] [Abstract][Full Text] [Related]
18. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.
Batchu RB; Moreno AM; Szmania SM; Bennett G; Spagnoli GC; Ponnazhagan S; Barlogie B; Tricot G; van Rhee F
Cancer Res; 2005 Nov; 65(21):10041-9. PubMed ID: 16267030
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
[TBL] [Abstract][Full Text] [Related]
20. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
